Stockscreener 앱 받기
0.0114
45.71%
-0.0096
Virpax Pharmaceuticals Inc 주식(VRPX)의 최신 뉴스
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Head-To-Head Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) vs. Evotec (OTCMKTS:EVTCY) - Defense World
Virpax reports positive study results for pain management drug - MSN
Top Nanotechnology Stocks To Follow Today – August 25th - Defense World
Promising Nanotechnology Stocks To Watch Now – July 16th - Defense World
Promising Nanotechnology Stocks To Watch NowJuly 16th - MarketBeat
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Down 2.9% – Should You Sell? - Defense World
Promising Nanotechnology Stocks To Add to Your Watchlist – July 9th - Defense World
Top Nanotechnology Stocks To Follow NowJuly 10th - MarketBeat
Promising Nanotechnology Stocks To Add to Your WatchlistJuly 9th - MarketBeat
Nanotechnology Stocks To Watch Today – July 7th - Defense World
Nanotechnology Stocks To Research – July 3rd - Defense World
Best Nanotechnology Stocks To Add to Your WatchlistJune 16th - MarketBeat
Top Nanotechnology Stocks Worth WatchingJune 17th - MarketBeat
Best Nanotechnology Stocks To Keep An Eye OnJune 15th - MarketBeat
Nanotechnology Stocks To Watch NowJune 14th - MarketBeat
Promising Nanotechnology Stocks To ResearchJune 11th - MarketBeat
Nanotechnology Stocks To ResearchJune 8th - MarketBeat
Nanotechnology Stocks To Follow NowJune 9th - MarketBeat
Best Nanotechnology Stocks To Follow Today – May 31st - Defense World
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading 4.4% Higher – Still a Buy? - Defense World
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
Promising Nanotechnology Stocks To Watch Now – May 7th - The AM Reporter
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Up 5.5% – Here’s What Happened - Defense World
Virpax(R) Pharmaceuticals Announces Appointment of Michèle C. Linde, EVP, General Counsel - ACCESS Newswire
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Increase in Short Interest - Defense World
VRPX stock plunges to 52-week low, touches $1.07 - Investing.com Australia
Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes - TipRanks
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split By Investing.com - Investing.com UK
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com
Breakthrough: Virpax's 5-Day Pain Drug Passes Critical Safety Test - Stock Titan
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET - MyChesCo
Could This Needle-Free COVID Vaccine Technology Transform Vaccine Delivery? - Stock Titan
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS - Business Wire
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Virpax lauds Nanomerics’ MET study with no severe side effects - Investing.com India
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - Stock Titan
VRPX stock touches 52-week low at $0.23 amid market challenges - Investing.com
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Yahoo Finance
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - Stock Titan
Virpax Pharmaceuticals director resigns due to compliance - Investing.com
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference - Business Wire
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - GlobeNewswire
Virpax Pharmaceuticals sets public offering at $0.20 per share - Investing.com
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals announces board member resignation - Investing.com
Virpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management Innovation - MyChesCo
Why Is Virpax Pharmaceuticals Stock Gaining On Friday? - Benzinga
Virpax Pharmaceuticals extends NIH pain management research - Investing.com
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering - GlobeNewswire
VRPX stock touches 52-week low at $0.46 amid market challenges - Investing.com
Virpax Pharmaceuticals Faces Nasdaq Delisting Risk - TipRanks
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com
Virpax Pharmaceuticals extends financing negotiation rights By Investing.com - Investing.com UK
Virpax Pharmaceuticals announces auditor change and board resignation By Investing.com - Investing.com Canada
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - Business Wire
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - FinancialContent
Virpax Pharmaceuticals pays off $2.5 million secured note early - Investing.com
Virpax Regains Compliance with Nasdaq Minimum Bid Price | User | ricentral.com - FinancialContent
3 Penny Stocks to Watch Now, 7/23/24 - Nasdaq
Maxim Group Upgrades Virpax Pharmaceuticals (VRPX) - Nasdaq
Virpax Pharmaceuticals Reports Promising Results for Pain Relief Drug - MyChesCo
Latest Cannabis Hires And Board Changes, Here's What You Need To Know - Benzinga
Virpax Pharma rises as pain medication shows promise in animal study - TradingView
1.84%
0.50%
자본화:
|
볼륨(24시간):